Epigenetic Therapies and Technologies: World Market Prospects 2013-2023 - Siouxland News - KMEG 14 and FOX 44
Member Center:
Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.
SOURCE Reportlinker
NEW YORK, March 4, 2013 Reportlinker.com announces that a new market research report is available in its catalogue:
Epigenetic Therapies and Technologies: World Market Prospects 2013-2023
http://www.reportlinker.com/p0692157/Epigenetic-Therapies-and-Technologies-World-Market-Prospects-2013-2023.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy
Report Details
How to find trends and revenue predictions for epigenetics
What does the future hold for epigenetic applications? Visiongain's new report gives you revenue predictions to 2023 for those therapies, technologies and diagnostic products. There you find sales data, R&D trends, opportunities and commercial prospects.
That analysis lets you assess forecasted sales at overall world market, submarket, product, regional and national level. You discover the potential of the industry and market for epigenetics, seeing where that field is heading.
Forecasts and other analyses to help you find the best opportunities
In our study you find revenue forecasting to 2023, historical data, growth rates and market shares. Also, you see qualitative analysis (SWOT and STEP), business news, outlooks and developmental trends (R&D). You gain 70 tables, 47 charts and two research interviews.
Our work lets you investigate the most lucrative areas in that industry and market. Those technologies hold great promise.
The following sections show what you see in our updated report.
You discover prospects for the world market and submarkets
Along with revenue prediction for the overall world market, you see individual forecasts for three epigenetic submarkets to 2023: • Therapies• Technologies• Diagnostics.
You can gain advantages by understanding trends, opportunities and challenges for epigenetics. Our investigation shows what will stimulate and restrain business.
Also, how will existing and expected products - Vidaza, Dacogen, Zolinza, Istodax, Belinostat and Faridak - perform at world level to 2023? You see forecasts and discussions for those drugs.
Our work also breaks the overall world forecast into leading geographical markets.
What prospects for leading regions and countries?
Developments worldwide will influence the market from 2013. There are many opportunities for healthcare companies large and small.
You discover individual revenue forecasts to 2023 for eight national markets and two regional blocks. Find relevant overall sales:• US• Canada• Japan• Germany, France, UK, Italy and Spain (EU5 countries)• Europe• Brazil, Russia, India and China (BRIC nations, grouped analysis).
You find potential. High sales growth will occur in established pharma markets and in developing countries, our analyses show. In particular, drug launches will change the commercial landscape to 2023.
Research and development - see trends and possibilities
What's happening in epigenetic R&D? You see trends and outlooks there:
• HDAC inhibitors
• DNMT inhibitors
• Treatments targeting other enzymes
• MiRNA therapy
• Diagnostics pipeline.
Our study also discusses these technologies, among others:• New drug targets• Biomarkers• Bioinformatics• Next generation sequencing.
Discover progress. You assess innovations affecting the industry's future - hear about developments and find their significance. Our work explains, exploring many issues.
What affects the application of epigenetics?
Our report discusses issues and events affecting that science, industry and market from 2013 onwards:
• Cancer research and treatment
• DNA hypomethylation in autoimmune diseases
• Neurodegenerative diseases
• Neurological disorders
• Understanding of epigenetic markers and mechanisms.
Also, you find coverage of these aspects of the field:• Genomics, proteomics and metabolomics• Translational research• Licensing, outsourcing and academic collaborations• Developments with stem cells• Orphan indications and patient subpopulations• Companion diagnostics and stratified medicine.
See what the future holds. You investigate technological, commercial, economic and political matters, with emphasis on companies, competition and business outlooks.
Leading companies and market value
Overall world revenue for epigenetic applications will reach $2,518m in 2013, our report forecasts. The R&D pipeline is diverse and promising. That industry holds great potential for further investment, development and growth.
In our study you find discussions of these organisations and many others:• Celgene• Eisai• Merck & Co.• Roche• Astex Pharmaceuticals• Exact Sciences• Orion Genomics.
This decade, many opportunities will arise. Our work shows you the technological and commercial possibilities.
Nine ways Epigenetic Therapies and Technologies: World Market Prospects 2013-2023 helps you
To sum up, our investigation gives you the following knowledge on the topic:
• Forecasted revenues to 2023 for the overall world market and 3 submarkets - you discover prospects for the industry's future
• Predicted revenues of 6 products to 2023 - you find prospects for drugs, both existing brands and those awaiting launch
• Market forecasting to 2023 for US, Canada, Japan, Germany, France, UK, Spain, Italy, BRIC nations and Europe - you see national and regional outlooks
• Assessments of companies - you find activities, products, strategies and outlooks
• Review of R&D by technology and disease - you hear about progress in established and emerging research areas
• Opinions on the sector - you read our interviews with leaders in that industry
• Competition and opportunities influencing sales - you see what affects the future
• Discussions of what stimulates and restrains the industry and market - you explore business trends, drivers and restraints
• Prospects for established firms and those seeking to enter the sector - you assess needs, practices and outlooks for success.
You gain information found nowhere else
That work gives independent analysis from our primary and secondary research. You receive business intelligence found only in our study, seeing where prospects are lucrative.
With our report you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses and decisions, saving time and getting you recognition for technological and commercial insight.
Ordering now lets you discover commercial prospects to 2023 for epigenetics
Visiongain's study is for everyone needing forward-looking analysis of pharmaceutical and diagnostic biotechnology. You find data, trends and predictions. Please ask for our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Table of Contents1. Executive Summary
1.1 Epigenetic Therapies and Technologies: World Market Review1.2 Report Contents1.3 Research and Analysis Methods
2. An Introduction to Epigenetics
2.1 How is Epigenetics Defined?
2.1.1 Epigenetic Mechanisms
2.1.2 A Brief History of Epigenetic Research
2.2 The Links between Epigenetics and Disease
2.2.1 The Role of Lifestyle in Epigenetics
2.2.2 Epigenetics and Cancer
2.2.3 Epigenetics in Inherited Disorders
2.2.4 Epigenetics in Neurological Diseases
2.3 Epigenetics for Disease Diagnosis
2.3.1 Diagnosing for Breast Cancer
2.3.2 Colorectal Cancer: The Importance of Early Diagnosis
2.3.3 Diagnostics for Lung Cancer: Difficulty in Accessing Samples
2.3.4 Diagnostics for Prostate Cancer
2.4 The Use of Epigenetics in Treating Disease
2.4.1 DNA Methyltransferase (DNMT) Inhibitors
2.4.1.1 Myelodysplastic Syndromes (MDS)
2.4.2 Histone Deacetylase (HDAC) Inhibitors
2.4.2.1 Cutaneous T Cell Lymphoma (CTCL)
2.4.2.2 Peripheral T Cell Lymphoma (PTCL)
2.5 Drug Discovery and Development Tools Using Epigenetics
2.5.1 Bisulphite Screening for DNA Methylation
2.5.2 Chromatin Immunoprecipitation (ChIP) for Histone Modification
3. The Epigenetic Therapies and Technologies Market 2013-2023
3.1 The Epigenetic Therapies and Technologies Market 2011-20123.1.1 Leading Sectors of the Market 2011-20123.2 The Epigenetic Therapies and Technologies Market 2013-20233.2.1 The Epigenetic Therapies and Technologies Market: Overall Revenue Forecast 2013-20233.2.2 What Will Drive Revenue Growth for Epigenetic Therapies and Technologies?3.2.3 Rising Importance for Diagnostics Revenue 2013-20233.3 Epigenetic Therapies Submarket 2013-20233.3.1 Epigenetic Therapies Submarket: Revenue Forecast 2013-20233.3.2 Factors Influencing Epigenetic Therapy Uptake and Revenues 2013-20233.4 Epigenetic Technologies Submarket 2013-20233.4.1 Epigenetic Technologies Submarket: Revenue Forecast 2013-20233.4.2 Epigenetic Technologies Submarket: Drivers and Restraints 2013-20233.5 Epigenetic Diagnostics Submarket 2013-20233.5.1 Epigenetic Diagnostics Submarket: Revenue Forecast 2013-20233.5.2 New Product Launches to Drive Growth 2013-2023
4. Leading National Epigenetic Therapy and Technology Markets 2013-2023
4.1 Leading National Markets for Epigenetic Therapies and Technologies 2011-2012
4.2 Leading National Markets: Revenue Forecasts 2013-2023
4.2.1 The Continued Dominance of Western Markets 2013-2023
4.3 The North American Market 2013-2023
4.3.1 The US: The World's Largest Market for Epigenetic Therapies and Technologies 2013-2023
4.3.2 Canada: Revenues 2013-2023
4.4 The European Market 2011-2012
4.4.1 Leading National Markets in Europe: Revenue Forecasts 2013-2023
4.4.2 Germany: Revenues 2013-2023
4.4.3 The UK: A Leading Market for Epigenetics Research
4.5 Japan: Recent Entry of the Epigenetic Therapies Market
4.6 Epigenetics in Emerging Markets
4.6.1 BRIC Nations: Rising Importance for Epigenetic Therapies and Technologies 2013-2023
5. Epigenetic Therapies Market 2013-2023
5.1 Changes to the Epigenetic Therapies Market 2013-20235.2 Vidaza: The First Epigenetic Therapy Approved5.2.1 Vidaza: Strong Revenue Growth 2004-20115.2.2 Development as a Combination Therapy to Drive Growth5.2.3 Vidaza: Revenue Forecast 2013-20235.3 Dacogen5.3.1 Revenue Performance 2004-20115.3.2 Approval in the EU in 2012 to Drive Revenue Growth5.3.3 Dacogen: Revenue Forecast 2013-20235.4 Zolinza5.4.1 Zolinza as a Potential Treatment for Multiple Myeloma5.4.2 Zolinza: Revenue Forecast 2013-20235.5 Istodax5.5.1 US PTCL Approval5.5.2 Istodax: Revenue Forecast 2013-20235.6 Rich Pipeline for HDAC Inhibitors in 20125.6.1 Belinostat: A Selective HDAC Inhibitor for PTCL5.6.2 Faridak for Velcade-Refractory Multiple Myeloma5.6.3 Entinostat (Syndax Pharmaceuticals)5.6.4 Resminostat (4SC)5.6.5 Pracinostat: The First Epigenetic Therapy Developed in Singapore5.6.6 Mocetinostat Has Been Tested in More Than 12 Clinical Trials5.6.7 Quisinostat (Centocor Research & Development)5.6.8 Rocilinostat (Acetylon Pharmaceuticals)5.6.9 CHR-3996 (Chroma Therapeutics)5.6.10 Givinostat for Cancer, Autoimmune and Neurodegenerative Diseases5.6.11 SHP-141 (Shape Pharmaceuticals)5.6.12 EVP-0334 (EnVivo Pharmaceuticals/MethylGene)5.6.13 4SC-202 (4SC)5.6.14 Tefinostat (Chroma Therapeutics)5.6.15 CXD101 (Celleron Therapeutics)5.6.16 Repligen: Epigenetic Therapies for Orphan Neurodegenerative Indications5.6.17 Abexinostat (Pharmacyclics/Servier)5.7 DNMT Inhibitor Pipeline 20125.7.1 SGI-110: A Second Generation DNMT Inhibitor5.8 Pipeline Treatments Targeting Other Epigenetic Enzymes 20125.8.1 EPZ-5676: The First Clinical-Stage HMT Inhibitor5.8.2 Oryzon Genomics: Targeting LSD15.8.3 Salarius Pharmaceuticals5.8.4 Resverlogix Advancing BET Protein Inhibitors5.9 MiRNA Therapy Pipeline 20125.9.1 Miravirsen (Santaris Pharma) is the Only Clinical-Stage miRNA Therapy5.9.2 MRX34 (Mirna Therapeutics)5.9.3 Regulus Therapeutics Is Collaborating with Big Pharma Players5.10 Leading Epigenetic Therapy Manufacturers and Developers 20125.10.1 Celgene: Market Leader 2011-20125.10.2 Eisai5.10.3 Merck & Co.5.10.4 TopoTarget: Assessing Drug Commercialisation Strategies5.10.5 Syndax Pharmaceuticals5.10.6 4SC5.10.7 Astex Pharmaceuticals is an Experienced Epigenetic Therapy Developer5.10.8 Curis is Developing Multi-Targeted Therapies5.10.9 CellCentric: Industry and Academic Collaboration for Drug Development5.10.10 Constellation Pharmaceuticals5.10.11 EpiTherapeutics5.10.12 Epizyme Has Signed Valuable Big Pharma Collaboration Agreements5.10.13 IkerChem: HDAC and DNMT Inhibitors in Cancer and CNS Disorders5.10.14 Karus Therapeutics: HDAC Inhibitors for Inflammatory Diseases and Cancer
6. Epigenetic Diagnostics Market 2013-2023
6.1 Development of the Epigenetic Diagnostics Market 2013-2023
6.1.1 LDTs vs. IVDs: Two Diagnostic Development Strategies
6.2 Epigenetic Diagnostics Marketed 2012
6.2.1 Epi proColon 2.0 (Epigenomics)
6.2.1.1 ColoVantage (Quest Diagnostics)
6.2.1.2 Septin9 LDT (ARUP Laboratories)
6.2.2 ColoSure (LabCorp)
6.2.3 ConfirmMDx for Prostate Cancer (MDxHealth)
6.2.3.1 Gene Methylation in Prostate Cancer (LabCorp)
6.2.4 Epi proLung (Epigenomics)
6.2.5 MGMT Gene Methylation Assay (LabCorp)
6.2.6 Bladder Cancer Testing with CertNDx (Predictive Biosciences)
6.3 Epigenetic Diagnostics Pipeline 2012
6.3.1 The Future of Colorectal Cancer Testing
6.3.1.1 Cologuard: Using More Biomarkers to Improve Sensitivity
6.3.1.2 Orion Colorectal Cancer Risk Test (Orion Genomics)
6.3.1.3 PredictMDx (MDxHealth)
6.3.2 New Prognostic Tools in Development for Prostate Cancer
6.3.3 Lung Cancer
6.3.3.1 Lung Cancer Screening Test (Orion Genomics)
6.3.3.2 ConfirmMDx and InformMDx (MDxHealth)
6.3.4 Future Developments in Bladder Cancer Testing
6.3.4.1 Bladder Cancer Screening Test (Orion Genomics)
6.3.5 Other Cancer Tests in Development 2012
6.3.5.1 PredictMDx for Brain Cancer LDT (MDxHealth)
6.3.5.2 Pancreatic Cancer Prognostic Test (PrognosDx Health)
6.4 Leading Epigenetic Diagnostic Developers 2012
6.4.1 Epigenomics Markets Multiple Tests in the EU
6.4.1.1 Low Revenue in the EU 2010-2012
6.4.2 Exact Sciences and Colorectal Cancer Screening
6.4.3 MDxHealth: Targeting the US Diagnostics Market
6.4.3.1 Strong Revenue Growth 2009-2011
6.4.4 Orion Genomics Has Discovered More Than 100 Biomarkers
6.4.5 Predictive Biosciences
6.4.6 PrognosDx Health: Developing Epigenetic Prognostics
7. Epigenetic Technologies Market 2013-2023
7.1 Epigenetic Technology and Services Market 2013-20237.1.1 Outsourcing Epigenetic Discovery and Analysis7.2 Next Generation Sequencing (NGS)7.2.1 Lower Costs and Higher Speed for Expanded Research7.2.2 Bottlenecks in Bioinformatics7.2.3 Single Molecule Sequencing to Compete with NGS7.3 Future Developments in Chromatin Immunoprecipitation7.3.1 Considerations for ChIP-Seq7.4 Future Developments in Bisulphite Screening7.4.1 Techniques for Researching 5hmC Developed 20127.5 High Throughput Screening for Epigenetics7.6 Leading Providers of Epigenetic Technologies 20127.6.1 Active Motif7.6.2 Agilent Technologies: Measurement Tools for Epigenetic Research7.6.3 Diagenode7.6.4 DiscoveRx: Providing Tools to Research New Epigenetic Pathways7.6.5 EMD Millipore7.6.6 Epigentek Specialises in Epigenetic Technologies and Services7.6.7 Epiontis: Epigenetics in Regenerative Medicine7.6.8 Life Technologies: Cutting the Cost of NGS7.6.9 Qiagen is Developing Epigenetic Technologies and Diagnostics7.6.10 Roche
8. Research and Product Development Strategies in Epigenetics 2013-2023
8.1 The Epigenetic Therapies and Technologies Market by Disease 2013-2023
8.2 Present and Future Epigenetic Research in Cancer
8.2.1 Twin Studies Reveal Epigenetic Biomarkers in Breast Cancer
8.2.2 Colorectal Cancer: Beyond Two Well-Established Biomarkers
8.2.3 Prognostic Markers in Lung Cancer
8.2.4 Prostate Cancer: Advances in Diagnostics, but Little Progress in Epigenetic Therapies
8.3 DNA Hypomethylation in Autoimmune Diseases
8.3.1 Lupus
8.3.2 Rheumatoid Arthritis as a Target for Drug and Diagnostic Development
8.3.2.1 Case Study: Ignyta, Pioneering Epigenetic Diagnostics in Rheumatoid Arthritis
8.3.3 Diabetes Incidence is Linked to Ageing and Diet
8.4 Neurodegenerative Diseases
8.4.1 Alzheimer's Disease: Alleviation of Symptoms Using HDAC Inhibitors
8.4.2 Huntington's Disease: Epigenetic Drugs Approaching Clinical Development
8.5 Neurological Disorders
8.5.1 Drug Resistance in Schizophrenia
8.5.2 Autism is Linked to Many Genetic and Epigenetic Mutations
8.6 New Epigenetic Drug Targets
8.6.1 BET Proteins Are a Target in Many Therapeutic Areas
8.6.2 Assessing and Understanding DNA Hydroxymethylation
8.6.3 Sirtuins as an Underexploited HDAC Inhibitor Class
8.6.4 Histone Methyltransferase
8.6.4.1 Lysine Methyltransferase
8.6.4.2 Case Study: Domainex Developing HMT Inhibitors
8.6.4.3 Protein Arginine Methyltransferases: Overcoming Insufficient Potency
8.6.5 Lysine Demethylases Show Promise as Targets for Cancer Therapies
9. Epigenetic Therapies and Technologies: Industry Trends 2013-2023
9.1 Epigenetic Therapies and Technologies Market: Strengths and Weaknesses 2011-20129.1.1 Understanding Epigenetic Markers and Mechanisms9.1.2 Specificity of Current Epigenetic Therapies9.2 Epigenetic Therapies and Technologies Market: Opportunities and Threats 2013-20239.2.1 The Importance of Translational Research9.2.2 Developing Companion Diagnostics9.2.3 Long Therapeutic and Diagnostic Pipelines9.2.4 Combination Therapy with Epigenetic Drugs9.2.5 Epigenetic Therapies to Overcome Drug Resistance9.2.6 Drug Targets Beyond HDAC and DNMT Inhibition9.3 Epigenetic Therapies and Technologies: STEP Analysis 2013-20239.4 Social Factors Influencing Product Development9.4.1 Epigenetics and the Environment9.4.2 Epigenetics, Ageing, and Disease9.4.2.1 Rising Global Disease Incidence to Drive Epigenetics Market Growth9.4.3 Targeting Orphan Indications and Patient Subpopulations9.4.4 Epigenetics Can Lead to Personalised and Stratified Medicine9.5 Technological Developments to Aid Epigenetic Research9.5.1 Next-Generation Sequencing Improving Epigenetic Research9.5.2 Using Epigenetics to Drive Forward Stem Cell Research9.5.3 Complementary and Competing Technologies9.5.3.1 Genomics9.5.3.2 Proteomics9.5.3.3 Metabolomics: A Comparatively New Discipline9.6 Economic Factors9.6.1 The Cost of Epigenetic Research9.6.2 The Role of Big Pharma in the Epigenetics Market 2013-20239.6.2.1 Pfizer9.6.2.2 Novartis: Performing Epigenetic Research in China9.6.2.3 GSK Has Signed Many Deals in Epigenetics9.6.3 Major Licensing Deals in Epigenetics9.6.4 Epigenetic Business Models9.7 Political Issues9.7.1 Ethics in Epigenetic Research9.7.2 Collaboration in Epigenetic Research9.7.2.1 Structural Genomics Consortium9.7.2.2 NIH Roadmap Epigenetics Project9.7.2.3 International Human Epigenome Consortium9.7.2.4 Blueprint: Contributing to Global Epigenome Libraries
10. Research Interviews
10.1 Dr James Rusche, SVP R&D, Repligen
10.1.1 The Advantage in Using HDAC Inhibitors
10.1.2 Combination Therapy Using HDAC Inhibitors
10.1.3 Challenges in Developing Epigenetic Drugs
10.1.3.1 Challenges Specific to Selective HDAC Inhibitors
10.1.4 Partnering for Epigenetic Drug Development
10.2 Dr Simon Kerry, CEO, Karus Therapeutics
10.2.1 Differences in Developing Selective and pan-HDAC Inhibitors
10.2.2 HDAC Inhibitors for Cancer and Other Diseases
10.2.3 Comparison of Kinase Inhibitor and HDAC Inhibitor Development
10.2.4 The Future of Epigenetic R&D
11. Conclusions from Our Study
11.1 Drugs Account for Most Epigenetic Revenues in 201211.2 Growth Expected in All Sectors of the Epigenetics Market 2013-202311.2.1 Developed Markets to Dominate 2013-202311.3 Many Opportunities Exist for Market Entry
List of Tables
Table 1.1 Currency Exchange Rates, 2011
Table 2.1 Selected Enzymes Involved in Epigenetic Mechanisms
Table 2.2 Selected Treatments for MDS, 2012
Table 3.1 Epigenetic Therapies and Technologies Market by Sector, 2011
Table 3.2 Epigenetic Therapies and Technologies Market: Overall Market and Revenue Forecasts by Sector, 2011-2023
Table 3.3 Epigenetic Therapies and Technologies Market: Drivers and Restraints, 2013-2023
Table 3.4 Epigenetic Therapies and Technologies Submarket Shares, 2011-2023
Table 3.5 Epigenetic Therapies Submarket by Drug, 2011
Table 3.6 Epigenetic Therapies Submarket: Overall Submarket and Revenue Forecasts by Drug, 2011-2023
Table 3.7 Epigenetic Therapies Submarket: Drivers and Restraints, 2013-2023
Table 3.8 Epigenetic Technologies Submarket: Revenue Forecast, 2011-2023
Table 3.9 Epigenetic Technologies Submarket: Drivers and Restraints, 2013-2023
Table 3.10 Epigenetic Diagnostics Submarket: Revenue Forecast, 2011-2023
Table 3.11 Epigenetic Diagnostics Submarket: Drivers and Restraints, 2013-2023
Table 4.1 Epigenetic Therapies and Technologies Market by Country, 2011
Table 4.2 Epigenetic Therapies and Technologies in Developed Markets: Drivers and Restraints, 2013-2023
Table 4.3 Epigenetic Therapies and Technologies Market: Revenue Forecasts by Country, 2011-2023
Table 4.4 Epigenetic Therapies and Technologies in Emerging Markets: Drivers and Restraints, 2013-2023
Table 4.5 Epigenetic Therapies and Technologies: Market Shares by Country, 2011-2023
Table 4.6 US Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Table 4.7 Canadian Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Table 4.8 European Epigenetic Therapies and Technologies Market by Country, 2011
Table 4.9 Selected Epigenetic Companies Headquartered in the EU, 2012
Table 4.10 European Epigenetic Therapies and Technologies Market: Revenue Forecasts by Leading Country, 2011-2023
Table 4.11 German Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Table 4.12 UK Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Table 4.13 Japanese Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Table 4.14 BRIC Nations (Grouped) Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Table 5.1 Epigenetic Therapies Submarket: Drug Revenue Shares, 2011-2023
Table 5.2 Vidaza: Revenue, 2004-2011
Table 5.3 Vidaza: Revenue by Region, H1 2011-2012
Table 5.4 Vidaza: Revenue Forecast, 2011-2023
Table 5.5 Vidaza: Drivers and Restraints, 2013-2023
Table 5.6 Dacogen: Revenue and Royalty Revenue, 2006-2011
Table 5.7 Dacogen: Phase III Clinical Trials, 2012
Table 5.8 Dacogen: Drivers and Restraints, 2013-2023
Table 5.9 Dacogen: Revenue Forecast, 2011-2023
Table 5.10 Zolinza: Drivers and Restraints, 2013-2023
Table 5.11 Zolinza: Revenue Forecast, 2011-2023
Table 5.12 Istodax: Revenue, 2010-2011
Table 5.13 CTCL and PTCL Prevalence by Region
Table 5.14 Istodax: Drivers and Restraints, 2013-2023
Table 5.15 Istodax: Revenue Forecast, 2011-2023
Table 5.16 Selected HDAC Inhibitors in Development, 2012
Table 5.17 NCI Sponsored Trials of Belinostat, 2012
Table 5.18 Belinostat: Revenue Forecast, 2014-2023
Table 5.19 Faridak: Revenue Forecast, 2014-2023
Table 5.20 Drug Mechanisms Being Assessed in Clinical Trials for Breast Cancer and Multiple Myeloma, 2012
Table 5.21 Selected Pipeline for Other Epigenetic Enzyme Inhibitors, 2012
Table 5.22 Selected MiRNA Therapy Pipeline, 2012
Table 5.23 CellCentric's Research Institution Affiliations, 2012
Table 5.24 IkerChem Epigenetic Pipeline, 2012
Table 6.1 Pipeline and Marketed Epigenetic Colorectal Cancer Test Comparison, 2012
Table 6.2 Epigenomics: Revenue, 2010-2011
Table 6.3 MDxHealth: Pipeline, 2012
Table 6.4 MDxHealth: Revenue by Source, 2009-2011
Table 7.1 Fall in Average Cost of Sequencing the Human Genome, 2000-2012
Table 7.2 Selected Producers of Single-Molecule Sequencing Technologies, 2012
Table 7.3 Life Technologies: Revenue by Sector, 2010-2011
Table 8.1 Epigenetic Therapies and Technologies Market by Disease, 2011
Table 8.2 Prevalence of Cancers Targeted by Epigenetic Therapies, 2012
Table 9.1 Epigenetic Therapies and Technologies Market: Strengths and Weaknesses, 2011-2012
Table 9.2 Epigenetic Therapies and Technologies Market: Opportunities and Threats, 2013-2023
Table 9.3 Epigenetic Therapies and Technologies Market: STEP Analysis, 2013-2023
Table 9.4 Biomarker Development and Technologies Market Discipline, 2011
Table 9.5 Lucrative Licensing Deals for Epigenetic Therapies, 2011-2012
Table 9.6 Selected University Spin-Outs in the Epigenetics Industry, 1997-2011
Table 9.7 IHEC Member Organisations, 2012
Table 11.1 Epigenetic Therapies and Technologies Market by Sector, 2011-2023
Table 11.2 Epigenetic Therapies and Technologies Market by Region, 2011-2023
List of Figures
Figure 2.1 Stages of Cutaneous T Cell Lymphoma
Figure 2.2 Chromatin Immunoprecipitation (ChIP) Process
Figure 3.1 Epigenetic Therapies and Technologies Market by Sector, 2011
Figure 3.2 Epigenetic Therapies and Technologies Market: Overall Market Forecast, 2011-2023
Figure 3.3 Epigenetic Therapies and Technologies: Market Shares by Sector, 2017
Figure 3.4 Epigenetic Therapies and Technologies: Market Shares by Sector, 2023
Figure 3.5 Epigenetic Therapies Submarket by Drug, 2011
Figure 3.6 Epigenetic Therapies Submarket: Revenue Forecast 2011-2023
Figure 3.7 Epigenetic Technologies Submarket: Revenue Forecast, 2011-2023
Figure 3.8 Epigenetic Diagnostics Submarket: Revenue Forecast, 2011-2023
Figure 4.1 Epigenetic Therapies and Technologies Market by Country, 2011
Figure 4.2 Epigenetic Therapies and Technologies Market by Country, 2017
Figure 4.3 Epigenetic Therapies and Technologies Market by Country, 2023
Figure 4.4 US Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Figure 4.5 Canadian Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Figure 4.6 European Epigenetic Therapies and Technologies Market by Country, 2011
Figure 4.7 European Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Figure 4.8 French, Spanish and Italian Epigenetic Therapies and Technologies Markets: Revenue Forecasts, 2011-2023
Figure 4.9 German Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Figure 4.10 UK Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Figure 4.11 Japanese Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Figure 4.12 BRIC Nations (Grouped) Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Figure 5.1 Epigenetic Therapies: Submarket Shares by Drug, 2017
Figure 5.2 Epigenetic Therapies: Submarket Shares by Drug, 2023
Figure 5.3 Vidaza: Revenue, 2004-2011
Figure 5.4 Vidaza: Revenue by Region, H1 2011-2012
Figure 5.5 Vidaza: Revenue Forecast, 2011-2023
Figure 5.6 Vidaza and Dacogen: Chemical Structures
Figure 5.7 Dacogen: Revenue and Royalty Revenue, 2006-2011
Figure 5.8 Dacogen: Revenue Forecast, 2011-2023
Figure 5.9 Zolinza: Revenue Forecast, 2011-2023
Figure 5.10 Istodax: Revenue, 2010-2011
Figure 5.11 Istodax: Revenue Forecast, 2011-2023
Figure 5.12 HDAC Inhibitor Expected Approvals, 2014-2019
Figure 5.13 Belinostat: Revenue Forecast, 2011-2023
Figure 5.14 Faridak: Revenue Forecast, 2011-2023
Figure 5.15 Drug Mechanisms Being Assessed in Clinical Trials for Breast Cancer, 2012
Figure 6.1 Pipeline and Marketed Epigenetic Colorectal Cancer Test Comparison, 2012
Figure 6.2 Epigenomics: Revenue, 2010-2011
Figure 6.3 MDxHealth: Revenue by Source, 2009-2011
Figure 7.1 Fall in Average Cost of Sequencing the Human Genome, 2000-2012
Figure 7.2 Life Technologies: Revenue by Sector, 2010-2011
Figure 8.1 Epigenetic Therapies and Technologies Market by Disease, 2011
Figure 8.2 Prevalence of Cancers Targeted by Epigenetic Therapies, 2012
Figure 9.1 Biomarker Development and Technologies by Market Discipline, 2011
Figure 11.1 Epigenetic Therapies and Technologies Market by Sector, 2011-2023
Figure 11.2 Epigenetic Therapies and Technologies Market by Region, 2011-2023
Companies Listed
4SC4SC Discovery (part of 4SC)Abbott Laboratories (AbbVie)Accelerate Brain Cancer CureAccium BioSciencesAcetylon PharmaceuticalsActive MotifAgence Nationale de la Recherche (ANR) [France]Agilent TechnologiesAgiosAllos TherapeuticsAmerican Cancer SocietyAmgenApplied Biosystems (part of Life Technologies)ARUP LaboratoriesAstellas Venture ManagementAstex PharmaceuticalsAstraZenecaAton Pharma (part of Merck & Co.)Australian Alliance for EpigeneticsBayerBellBrook LabsBGI (formerly Beijing Genomics Institute)Biogen IdecBoehringer Mannheim (part of Roche)Boston Children's HospitalBrabraham Institute [UK]Bundesministerium für Bildung und Forschung (BMBF) [Germany]Cambridge Institute for Medical ResearchCanadian Epigenetics, Environment and Health ConsortiumCanadian Institutes for Health Research (CIHR)CanAm BioresearchCancer Research TechnologyCancer Research UKCelgeneCellCentricCelleron TherapeuticsCellzome (part of GSK)Center for Genome Science [South Korea]Centers for Medicare and Medicaid Services (CMS)Centocor Research & Development (part of J&J)Centre de Regulació Genòmica [Spain]Centre for Addiction and Mental Health [Canada]Centre for Genomic Regulation [Barcelona]Centre National de la Recherche Scientifique (CNRS)Chiron (part of Novartis)Chroma TherapeuticsClavis PharmaCompanion DxConstellation PharmaceuticalsCornell UniversityCreluxCurisDana-Farber Cancer InstituteDepartment of Biotechnology [India]DiagenodeDiscoveRxDomainexDurvizEisaiEli LillyElixir PharmaceuticalsEMA Committee for Medicinal Products for Human Use (CHMP)EMD Millipore (part of Merck KGaA)EnVivo PharmaceuticalsEpigenDxEpigenetics Dream TeamEpigenomicsEpigentekEpiontisEpiTherapeuticsEpizymeEuropean CommissionEuropean Institute of Oncology (IEO)European Medicines Agency (EMA)European Patent OfficeExact SciencesFlagship BiosciencesFood and Drug Administration (FDA) [US]Friedreich's Ataxia Research Alliance (FARA)Genentech (part of Roche)Genomic HealthGenpathway (part of Active Motif)Genzyme (part of Sanofi)Gloucester Pharmaceuticals (part of Celgene)Go FAR (Friedreich's Ataxia Research)GSKHarvard UniversityHealth CanadaHelicos BioSciencesHewlett-PackardIgnytaIkerChemImperial College LondonIndian Institute of Science Education and ResearchInstitute of Cancer Research [UK]Intelligent Bio-Systems (part of Qiagen)International Human Epigenome Consortium (IHEC)ItalfarmacoJ&JJanssen-CilagJapan Science and Technology Agency (JST)Japanese Society for EpigeneticsJohn Hopkins UniversityKarus TherapeuticsKing's College London (KCL)LabCorpLeukemia and Lymphoma Society (LLS)Life TechnologiesLouis Pasteur University of StrasbourgLundbeckfond VenturesM.D. Anderson Cancer CenterMacmillan Cancer SupportMassachusetts General HospitalMayo ClinicMcGill UniversityMDxHealthMEI PharmaMemorial Sloan-Kettering Cancer CenterMerck & Co.Merck KGaAMerck Serono VenturesMethylGeneMGI Pharma (part of Eisai)Michael J. Fox FoundationMicrogenics (part of Boehringer Mannheim)Millennium PharmaceuticalsMinistry of Health, Labor and Welfare (MHLW) [Japan]MiRevenMirna TherapeuticsMitomicsMount Sinai Medical CenterMultiple Myeloma Research FoundationMuscular Dystrophy Association (MDA)Myeloma UKMyriad GeneticsNational Ataxia Foundation (NAF)National Cancer Institute (NCI) [US]National Health Service (NHS) [UK]National Human Genome Research Institute (NHGRI) [US]National Institute for Health and Clinical Excellence (NICE) [UK]National Institute for Mental Health (NIMH) [US]National Institutes of Health (NIH) [US]NIH Roadmap Epigenomics Mapping Consortium [US]Nippon ShinyakuNovartisNovo NordiskNovo SeedsNycomedOdyssey MolecularOnyx PharmaceuticalsOrion GenomicsOryzon GenomicsOtsuka PharmaceuticalPacific BiosciencesPfizerPfizer Venture InvestmentsPharmacyclicsPharmion (part of Celgene)PLUS DiagnosticsPredictive BiosciencesPrognosDx HealthQiagenQuest DiagnosticsRegulus TherapeuticsRepligenResverlogixRoadmap Epigenomics Mapping Consortium [US]RocheRoche NimbleGen (part of Roche)S*BIO (part of Chiron)SABiosciences (part of Qiagen)Salarius PharmaceuticalsSanofiSantaris PharmaScottish Medicines Consortium (SMC)Seed CapitalServierShape PharmaceuticalsSiena BiotechSigma-AldrichSpectrum PharmaceuticalsStructural Genomics Consortium (SGC)Swiss LifeSyndax PharmaceuticalsSysmexTaiho PharmaceuticalTakedaTakeda Ventures Technology Strategy Board (TSB) [UK]Tensha TherapeuticsThe Automation Partnership (now TAP Biosystems)The Pharmaceutical Research and Manufacturers of America (PhRMA)Thomas Jefferson UniversityTopoTargetUniversity College London (UCL)University of BirminghamUniversity of California, Los Angeles (UCLA)University of California, San DiegoUniversity of CambridgeUniversity of ChicagoUniversity of Copenhagen University of EdinburghUniversity of LiègeUniversity of North Carolina University of NottinghamUniversity of OxfordUniversity of SouthamptonUniversity of Southern CaliforniaUniversity of the Basque CountryUniversity of TorontoUniversity of UtahUniversity of WuerzburgVentana Medical Systems (part of Roche)Wellcome TrustWistar InstituteWorld Health Organization (WHO)Yakult HonshaZoBio
To order this report:Therapy Industry: Epigenetic Therapies and Technologies: World Market Prospects 2013-2023
Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001
©2012 PR Newswire. All Rights Reserved.
 | 
Titan Broadcasting
Main Phone: 712-277-3554 
|
